Blood pressure lowering and renin-angiotensin system blockade

Journal of Hypertension, Supplement

Volumn 21, Issue 6, 2003, Pages

  Unger, Thomas ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b DAZ   (Germany)

Author keywords

Angiotensin II; Angiotensin II receptor blockers; Angiotensin II receptors; Hypertension; Left ventricular hypertrophy; Myocardial infarction; Nerve regeneration; Stroke; Telmisartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; TELMISARTAN;

ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; CELL GROWTH; CONFERENCE PAPER; DRUG MECHANISM; ENDOTHELIUM LESION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; VASOCONSTRICTION;

EID: 0042471623     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200307006-00002     Document Type: Conference Paper

References (41)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-1263.
3. Lucius R, Gallinat S, Busche S, Rosenstiel P, Unger T. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999; 56:1008-1019.
4. Culman J, Baulmann J, Blume A, Unger T. The renin-angiotensin system in the brain: an update. J Renin Angiotensin Aldosterone Syst 2001; 2:96-102.
5. Timmermans PBWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-251.
6. de Gasparo M, Bullock GR. The AT1 and AT2 angiotensin receptors. In: Oparil S, Weber MA (editors). Hypertension: a companion to Brenner and Rector's The Kidney, Philadelphia: W.B. Saunders Company; 2000, pp. 100-110.
7. Obermuller N, Unger T, Culman J, Gohlke P, de Gasparo M, Bottari SP. Distribution of angiotensin II receptor subtypes in rat brain nuclei. Neurosci Lett 1991; 132:11-15.
8. 4 receptors. J Hypertens 1998; 16:2027-2037.
9. 2 receptor: new insights into an old system. Regul Pept 2001; 99:175-182.
10. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician 2002; 66:461-468.
11. Hernandez-Hernandez R, Sosa-Canache B, Velasco M, Armas-Hernandez MJ, Armas-Padilla MC, Cammarata R. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002; 16(suppl 1): S93-S99.
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
13. Coats AJ. Angiotensin type-1 receptor blockers in heart failure. Prog Cardiovasc Dis 2002; 44:231-242.
14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
15. Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8:578-583.
16. Böhm M, Lee M, Kreutz R, Kim S, Schinke M, Djavidani B, et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13:891-899.
17. Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28:397-402.
18. Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19:1079-1099.
19. Busche S, Gallinat S, Bohle RM, Reinecke A, Seebeck J, Franke F, et al. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol 2000; 157:605-611.
20. Zhu YZ, Zhu Y-C, Li J, Schäfer H, Schmidt W, Yao T, et al. Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. J Renin Angiotensin Aldosterone Syst 2000; 1:257-262.
21. Devereux RB, Pickering TG, Harshfield GA, Kleinert HD, Denby L, Clark L, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983; 68:470-476.
22. Böhm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163/164:217-221.
23. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1999; 98:2037-2042.
24. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001; 14:174-182.
25. Dahlöf B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
26. Kannel WB. Influence of multiple risk factors on the hazard of hypertension. J Cardiovasc Pharmacol 1990; 16(suppl 5):S53-S57.
27. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89(suppl 2A):3A-10A.
28. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98:2572-2579.
29. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
30. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31:349-355.
31. 1 receptor antagonism, ACE inhibition and combined treatment. Effects on mortality, functional and morphological parameters after experimental myocardial infarction in stroke prone SHRs. Hypertension 1999; 34:696.
32. Unger T, Badoer E, Ganten D, Lang RE, Rettig R. Brain angiotensin: pathways and pharmacology. Circulation 1988; 77:140-154.
33. 2 receptors. Blood Press 1996; 5(suppl 2):47-52.
34. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens 2002; 16(suppl 3):S64-S70.
35. 2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188:661-670.
36. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2399.
37. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
38. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
39. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
40. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
41. 1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298:62-70.